In this audio interview, Douglas K. Devries, OD, discusses the negative impact of undiagnosed and untreated ocular surface disease. He give pearls for comanaging cataract surgery patients, screening for meibomian gland dysfunction, and approaching OSD management in patients with comorbid conditions.
Supported by unrestricted educational grants from Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision
This podcast has no credit associated with it.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty have the following financial relationships with commercial interests:
Douglas K. Devries, OD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant and Speakers Bureau: Alcon, Bausch+ Health, Bio Tissue, Dompe, Eyevance, Johnson & Johnson Vision, Lumeris, Novartis, OcuSoft, Sun, and TearLab, Share/Stockholder: RPS.
Erin K. Fletcher, MIT, director of compliance and education; Evolve; and Kate Fehlhaber, PhD, writer, have no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Carl Zeiss Meditec, Inc., Glaukos, or Johnson & Johnson Vision.
By: Douglas K. Devries